Mark Heiman
Chief Science Officer at Scioto Biosciences · Executive at Microbiome Therapeutics
Carmel, Indiana, United States
Find your path to Mark
29 people in our graph share verified history with Mark — schools, employers, funds. One of them is your warm intro.
About
Mark Heiman is Chief Scientific Officer at Scioto Biosciences, Inc. He earned a Ph.D. in physiology from LSU School of Medicine in 1978, completed postdoctoral training in neuroendocrinology at the IU School of Medicine, and co-invented the drug Lanreotide with David Coy at Tulane University; he later joined Lilly Research Labs in 1987, where his work addressed growth hormone secretion, leptin, and ghrelin, and he served as CSO of Obesity Research before retiring in 2009. He subsequently cofounded MicroBiome Therapeutics, serving as CSO and Vice President of Research, and was named a Fellow of The Obesity Society in 2014.
Chief Science Officer at Scioto Biosciences
Intro paths
In turn, Mark can intro founders to Scioto Biosciences's investors below.
Scioto Biosciences's investors · 5
Co-founders at Scioto Biosciences
Executive at Microbiome Therapeutics
Intro paths
In turn, Mark can intro founders to Microbiome Therapeutics's investors below.
Experience
- Scioto Biosciences, IncCSOcurrent2018 — presentGreater Indianapolis
- Microbiome TherapeuticsCSO2010 — 2018Greater New Orleans Region
- Eli Lilly and CompanyResearch Fellow2008 — 2009Eli Lilly and Compnay
- Eli Lilly and CompanyCSO for Obesity2004 — 2008
- Eli Lilly and CompanySenior Scientist => Fellow1987 — 2004Greater Indianapolis
Skills & more
+11 more
BiopharmaceuticalsOncologyImmunologyTranslational MedicineDiabetesIn VivoMolecular BiologyLead ChangePharmaceutical IndustryCROINDFrom Mark's professional profile.
Frequently asked questions
- Who is Mark Heiman?
- Mark Heiman is Chief Scientific Officer at Scioto Biosciences, Inc. He earned a Ph.D. in physiology from LSU School of Medicine in 1978, completed postdoctoral training in neuroendocrinology at the IU School of Medicine, and co-invented the drug Lanreotide with David Coy at Tulane University; he later joined Lilly Research Labs in 1987, where his work addressed growth hormone secretion, leptin, and ghrelin, and he served as CSO of Obesity Research before retiring in 2009. He subsequently cofounded MicroBiome Therapeutics, serving as CSO and Vice President of Research, and was named a Fellow of The Obesity Society in 2014.
- Where does Mark Heiman work?
- Mark Heiman is Chief Science Officer at Scioto Biosciences and Executive at Microbiome Therapeutics.
- Where did Mark Heiman go to school?
- Mark Heiman studied at Louisiana State University School of Medicine in New Orleans (Doctor of Philosophy (Ph.D.), Human Physiology); University of New Orleans (Bachelor of Arts (BA), Biology, General).
Same school
Also attended Louisiana State University School of Medicine in New Orleans1
Also attended University of New Orleans26
+ 20 more
Shared employers
Also worked at Scioto Biosciences, Inc3
Also worked at Eli Lilly and Company189
+ 183 more